Advantages of adipose tissue stem cells over CD34+ mobilization to decrease hepatic fibrosis in Wistar rats

Marcela M. De Luna-Saldivar, Iván A. Marino-Martinez, Moisés A. Franco-Molina, Lydia G. Rivera-Morales, Gabriela Alarcón-Galván, Paula Cordero-Pérez, Augusto Rojas-Martínez, Cristina Rodríguez-Padilla, Linda E. Muñoz-Espinosa

Research output: Contribution to journalArticle

Abstract

Introduction and Objectives: Chronic liver inflammation may lead to hepatic cirrhosis, limiting its regenerative capacity. The clinical standard of care is transplantation, although stem cell therapy may be an alternative option. The study aim was to induce endogenous hematopoietic stem cells (HSCs) with granulocyte colony stimulating factor (G-CSF) and/or intravenous administration of adipose tissue-derived mesenchymal stem cells (MSCs) to decrease hepatic fibrosis in an experimental model. Material and methods: A liver fibrosis model was developed with female Wistar rats via multiple intraperitoneal doses of carbon tetrachloride. Three rats were selected to confirm cirrhosis, and the rest were set into experimental groups to evaluate single and combined therapies of G-CSF-stimulated HSC mobilization and intravenous MSC administration. Results: Treatment with MSCs and G-CSF significantly improved alanine amino transferase levels, while treatment with G-CSF, MSCs, and G-CSF + MSCs decreased aspartate amino transferase levels. Hepatocyte growth factor (HGF) and interleukin 10 levels increased with MSC treatment. Transforming growth factor β levels were lower with MSC treatment. Interleukin 1β and tumor necrosis factor alpha levels decreased in all treated groups. Histopathology showed that MSCs and G-CSF reduced liver fibrosis from F4 to F2. Conclusions: MSC treatment improves liver function, decreases hepatic fibrosis, and plays an anti-inflammatory role; it promotes HGF levels and increased proliferating cell nuclear antigen when followed by MSC treatment mobilization using G-CSF. When these therapies were combined, however, fibrosis improvement was less evident.

Original languageEnglish
Pages (from-to)620-626
Number of pages7
JournalAnnals of Hepatology
Volume18
Issue number4
DOIs
Publication statusPublished - 1 Jul 2019

Fingerprint

Mesenchymal Stromal Cells
Adipose Tissue
Wistar Rats
Fibrosis
Stem Cells
Granulocyte Colony-Stimulating Factor
Liver
Liver Cirrhosis
Hematopoietic Stem Cell Mobilization
Hepatocyte Growth Factor
Therapeutics
Transferases
Carbon Tetrachloride
Proliferating Cell Nuclear Antigen
Transforming Growth Factors
Standard of Care
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Interleukin-1
Aspartic Acid

Bibliographical note

Copyright © 2019 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

De Luna-Saldivar, M. M., Marino-Martinez, I. A., Franco-Molina, M. A., Rivera-Morales, L. G., Alarcón-Galván, G., Cordero-Pérez, P., ... Muñoz-Espinosa, L. E. (2019). Advantages of adipose tissue stem cells over CD34+ mobilization to decrease hepatic fibrosis in Wistar rats. Annals of Hepatology, 18(4), 620-626. https://doi.org/10.1016/j.aohep.2018.12.005
De Luna-Saldivar, Marcela M. ; Marino-Martinez, Iván A. ; Franco-Molina, Moisés A. ; Rivera-Morales, Lydia G. ; Alarcón-Galván, Gabriela ; Cordero-Pérez, Paula ; Rojas-Martínez, Augusto ; Rodríguez-Padilla, Cristina ; Muñoz-Espinosa, Linda E. / Advantages of adipose tissue stem cells over CD34+ mobilization to decrease hepatic fibrosis in Wistar rats. In: Annals of Hepatology. 2019 ; Vol. 18, No. 4. pp. 620-626.
@article{051378883adc49108c086f56ffa4d477,
title = "Advantages of adipose tissue stem cells over CD34+ mobilization to decrease hepatic fibrosis in Wistar rats",
abstract = "Introduction and Objectives: Chronic liver inflammation may lead to hepatic cirrhosis, limiting its regenerative capacity. The clinical standard of care is transplantation, although stem cell therapy may be an alternative option. The study aim was to induce endogenous hematopoietic stem cells (HSCs) with granulocyte colony stimulating factor (G-CSF) and/or intravenous administration of adipose tissue-derived mesenchymal stem cells (MSCs) to decrease hepatic fibrosis in an experimental model. Material and methods: A liver fibrosis model was developed with female Wistar rats via multiple intraperitoneal doses of carbon tetrachloride. Three rats were selected to confirm cirrhosis, and the rest were set into experimental groups to evaluate single and combined therapies of G-CSF-stimulated HSC mobilization and intravenous MSC administration. Results: Treatment with MSCs and G-CSF significantly improved alanine amino transferase levels, while treatment with G-CSF, MSCs, and G-CSF + MSCs decreased aspartate amino transferase levels. Hepatocyte growth factor (HGF) and interleukin 10 levels increased with MSC treatment. Transforming growth factor β levels were lower with MSC treatment. Interleukin 1β and tumor necrosis factor alpha levels decreased in all treated groups. Histopathology showed that MSCs and G-CSF reduced liver fibrosis from F4 to F2. Conclusions: MSC treatment improves liver function, decreases hepatic fibrosis, and plays an anti-inflammatory role; it promotes HGF levels and increased proliferating cell nuclear antigen when followed by MSC treatment mobilization using G-CSF. When these therapies were combined, however, fibrosis improvement was less evident.",
author = "{De Luna-Saldivar}, {Marcela M.} and Marino-Martinez, {Iv{\'a}n A.} and Franco-Molina, {Mois{\'e}s A.} and Rivera-Morales, {Lydia G.} and Gabriela Alarc{\'o}n-Galv{\'a}n and Paula Cordero-P{\'e}rez and Augusto Rojas-Mart{\'i}nez and Cristina Rodr{\'i}guez-Padilla and Mu{\~n}oz-Espinosa, {Linda E.}",
note = "Copyright {\circledC} 2019 Fundaci{\'o}n Cl{\'i}nica M{\'e}dica Sur, A.C. Published by Elsevier Espa{\~n}a, S.L.U. All rights reserved.",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.aohep.2018.12.005",
language = "English",
volume = "18",
pages = "620--626",
journal = "Annals of Hepatology",
issn = "1665-2681",
publisher = "Mexican Association of Hepatology",
number = "4",

}

De Luna-Saldivar, MM, Marino-Martinez, IA, Franco-Molina, MA, Rivera-Morales, LG, Alarcón-Galván, G, Cordero-Pérez, P, Rojas-Martínez, A, Rodríguez-Padilla, C & Muñoz-Espinosa, LE 2019, 'Advantages of adipose tissue stem cells over CD34+ mobilization to decrease hepatic fibrosis in Wistar rats', Annals of Hepatology, vol. 18, no. 4, pp. 620-626. https://doi.org/10.1016/j.aohep.2018.12.005

Advantages of adipose tissue stem cells over CD34+ mobilization to decrease hepatic fibrosis in Wistar rats. / De Luna-Saldivar, Marcela M.; Marino-Martinez, Iván A.; Franco-Molina, Moisés A.; Rivera-Morales, Lydia G.; Alarcón-Galván, Gabriela; Cordero-Pérez, Paula; Rojas-Martínez, Augusto; Rodríguez-Padilla, Cristina; Muñoz-Espinosa, Linda E.

In: Annals of Hepatology, Vol. 18, No. 4, 01.07.2019, p. 620-626.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Advantages of adipose tissue stem cells over CD34+ mobilization to decrease hepatic fibrosis in Wistar rats

AU - De Luna-Saldivar, Marcela M.

AU - Marino-Martinez, Iván A.

AU - Franco-Molina, Moisés A.

AU - Rivera-Morales, Lydia G.

AU - Alarcón-Galván, Gabriela

AU - Cordero-Pérez, Paula

AU - Rojas-Martínez, Augusto

AU - Rodríguez-Padilla, Cristina

AU - Muñoz-Espinosa, Linda E.

N1 - Copyright © 2019 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Introduction and Objectives: Chronic liver inflammation may lead to hepatic cirrhosis, limiting its regenerative capacity. The clinical standard of care is transplantation, although stem cell therapy may be an alternative option. The study aim was to induce endogenous hematopoietic stem cells (HSCs) with granulocyte colony stimulating factor (G-CSF) and/or intravenous administration of adipose tissue-derived mesenchymal stem cells (MSCs) to decrease hepatic fibrosis in an experimental model. Material and methods: A liver fibrosis model was developed with female Wistar rats via multiple intraperitoneal doses of carbon tetrachloride. Three rats were selected to confirm cirrhosis, and the rest were set into experimental groups to evaluate single and combined therapies of G-CSF-stimulated HSC mobilization and intravenous MSC administration. Results: Treatment with MSCs and G-CSF significantly improved alanine amino transferase levels, while treatment with G-CSF, MSCs, and G-CSF + MSCs decreased aspartate amino transferase levels. Hepatocyte growth factor (HGF) and interleukin 10 levels increased with MSC treatment. Transforming growth factor β levels were lower with MSC treatment. Interleukin 1β and tumor necrosis factor alpha levels decreased in all treated groups. Histopathology showed that MSCs and G-CSF reduced liver fibrosis from F4 to F2. Conclusions: MSC treatment improves liver function, decreases hepatic fibrosis, and plays an anti-inflammatory role; it promotes HGF levels and increased proliferating cell nuclear antigen when followed by MSC treatment mobilization using G-CSF. When these therapies were combined, however, fibrosis improvement was less evident.

AB - Introduction and Objectives: Chronic liver inflammation may lead to hepatic cirrhosis, limiting its regenerative capacity. The clinical standard of care is transplantation, although stem cell therapy may be an alternative option. The study aim was to induce endogenous hematopoietic stem cells (HSCs) with granulocyte colony stimulating factor (G-CSF) and/or intravenous administration of adipose tissue-derived mesenchymal stem cells (MSCs) to decrease hepatic fibrosis in an experimental model. Material and methods: A liver fibrosis model was developed with female Wistar rats via multiple intraperitoneal doses of carbon tetrachloride. Three rats were selected to confirm cirrhosis, and the rest were set into experimental groups to evaluate single and combined therapies of G-CSF-stimulated HSC mobilization and intravenous MSC administration. Results: Treatment with MSCs and G-CSF significantly improved alanine amino transferase levels, while treatment with G-CSF, MSCs, and G-CSF + MSCs decreased aspartate amino transferase levels. Hepatocyte growth factor (HGF) and interleukin 10 levels increased with MSC treatment. Transforming growth factor β levels were lower with MSC treatment. Interleukin 1β and tumor necrosis factor alpha levels decreased in all treated groups. Histopathology showed that MSCs and G-CSF reduced liver fibrosis from F4 to F2. Conclusions: MSC treatment improves liver function, decreases hepatic fibrosis, and plays an anti-inflammatory role; it promotes HGF levels and increased proliferating cell nuclear antigen when followed by MSC treatment mobilization using G-CSF. When these therapies were combined, however, fibrosis improvement was less evident.

UR - http://www.scopus.com/inward/record.url?scp=85069237179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069237179&partnerID=8YFLogxK

U2 - 10.1016/j.aohep.2018.12.005

DO - 10.1016/j.aohep.2018.12.005

M3 - Article

C2 - 31147180

AN - SCOPUS:85069237179

VL - 18

SP - 620

EP - 626

JO - Annals of Hepatology

JF - Annals of Hepatology

SN - 1665-2681

IS - 4

ER -

De Luna-Saldivar MM, Marino-Martinez IA, Franco-Molina MA, Rivera-Morales LG, Alarcón-Galván G, Cordero-Pérez P et al. Advantages of adipose tissue stem cells over CD34+ mobilization to decrease hepatic fibrosis in Wistar rats. Annals of Hepatology. 2019 Jul 1;18(4):620-626. https://doi.org/10.1016/j.aohep.2018.12.005